Page 1

VOR Vor Reports Second Quarter 2021 Financial Results and Provides Company Update August 9 , 2021 • On track to report initial VOR33 clinical data in the first half of 2022 • Announced collaborations with Abound Bio and Janssen to develop novel treatment systems for hematologic malignancies • Initiated build - out of in - house clinical manufacturing facility CAMBRIDGE , Mass . , Aug. 09 , 2021 ( GLOBE NEWSWIRE ) -- Vor Biopharma ( Nasdaq : VOR or the Company ) , a cell and genome engineering company , today reported financial results for the three - month period ended June 30 , 2021 , and provided a business update . " Vor is pioneering engineered hematopoietic stem cell ( eHSC ) therapies combined with targeted cancer therapies , and this quarter , we made several important advancements towards the clinic , and expanded our platform as we continue our mission to change the treatment paradigm in oncology , " said Robert Ang , MBBS , MBA , Vor's President and Chief Executive Officer . " We are making progress in our VOR33 Phase 1 / 2a trial with site initiation activities well underway and we remain on track to release initial clinical data in the first half of 2022. We are proud to have begun construction on our own manufacturing facility , which is another critical milestone in our journey to develop novel treatment systems for patients facing acute myeloid leukemia and other serious blood cancers . " Corporate Highlights • Expect to enroll first patient in VOR33 acute myeloid leukemia ( AML ) Phase 1 / 2a clinical trial in the next few months . VOR33 is the Company's lead product candidate , consisting of CRISPR genome - edited hematopoietic stem and progenitor cells that have been engineered to lack the CD33 protein . It is designed to replace the standard of care in transplant settings for patients suffering from AML and potentially other hematologic malignancies . The primary endpoint assessing the safety of VOR33 is the incidence of successful engraftment at 28 days . The Company remains on track to report initial clinical data in the first half of 2022 . • Signed collaborations with Abound Bio and Janssen , expanding Vor's platform to explore additional companion therapy opportunities for eHSCs . A key strategic initiative for Vor is to pair future engineered hematopoietic stem cell ( eHSC ) product candidates with companion therapeutics beyond VCAR33 . o In June , the Company entered into a multi - year strategic collaboration with Abound Bio , a biotechnology company generating novel antibody - based biological therapeutics for cancer , led by world - renowned pioneers in antibody and cell therapy research . Under the terms of the collaboration with Abound Bio , the companies aim to develop single and multi - targeted chimeric antigen receptor T - cell ( CAR - T ) treatments . o In July , the Company formed a collaboration with Janssen Biotech , Inc. ( Janssen ) , one of the Janssen Pharmaceutical Companies of Johnson & Johnson . Under the terms of the collaboration with Janssen , Vor will investigate the combination of its eHSC platform with one of Janssen's bispecific antibodies into a novel treatment system for AML . • Initiated build - out of clinical manufacturing facility . The facility , located at Vor's corporate headquarters in Cambridge , MA , is designed to support clinical manufacturing for Vor's cell therapy programs , including both eHSCs and CAR - T therapeutic candidates , and to be current Good Manufacturing Practice ( cGMP ) compliant . Vor recently hired clinical manufacturing veterans Joseph Amico Sr. and Michael Pinaud to expand an already industry - leading CMC team and support the build - out of its manufacturing facility . By integrating research , manufacturing and quality control testing capabilities under one roof , Vor aims to achieve flexible manufacturing capacity and to reduce the complexity , time , and cost required to manufacture cell therapy candidates . • Building a world - class cell and genome engineering company with the appointment of a new Chairman and promotion of Chief People Officer . The Company's Board of Directors appointed Matthew R. Patterson to the role of Chairman . Mr. Patterson joined the board in 2020 and brings nearly 30 years of senior leadership experience having most recently served as co - founder and Chief Executive Officer of Audentes Therapeutics , Inc. , which was acquired by Astellas Pharma in January 2020. He succeeds Kush M. Parmar , MD , PhD , Managing Partner at 5AM Ventures , who will continue his service to Vor as a member of its Board of Directors . To further support the Company's rapid growth , Tania Philipp was promoted to Chief People Officer where she will continue to help build an industry - leading team with expertise across